Even Fidelity and Vanguard Are in on This Tiny Beast of a Stock

*Promoted by Shore Thing Media

Good morning, Chupacabra legends—Jason Bond here.

Let’s get after it.

Alright, fire up your coffee, load up your trading platform, and buckle the hell up—because we’re talkin’ SXTP. This isn’t your average pharma play, man.

So there’s this company, 60 Degrees Pharmaceuticals (Nasdaq: SXTP), and they’ve got a drug called ARAKODA, aka tafenoquine if you’re trying to impress your scientist friends. 

It was originally approved to fight off malaria—super useful, especially for troops overseas. Long half-life, military loved it, DoD was all in.

The U.S. Department of Defense? Yeah, they’ve been working with these guys. Not just casually either. The DoD has actually supported development of—Arakoda—which is an anti-malarial designed to keep soldiers healthy when they’re deployed in gnarly, mosquito-infested zones.

Makes sense, right? You’ve got troops in places where malaria is still a major threat, and the military needs something that actually works, long-term. Arakoda’s got a longer half-life than traditional malaria meds, which means fewer pills and better compliance. More effective protection. Super practical for combat zones.

But now, these guys are flipping the script and going after something else entirely: babesiosis.

Yeah, babesiosis. Most people haven’t even heard of it, but it’s this tick-borne parasite that messes with your red blood cells—hijacks them like some microscopic pirate. Causes fever, chills, fatigue, all that. And for older folks or people with compromised immune systems? It can get real serious.

Here’s where it gets super interesting: SXTP just got the green light from an IRB—that’s a review board for clinical trials—to launch a Phase II study using tafenoquine on people with chronic babesiosis. We're talking patients who’ve been battling this for six months or more and still aren’t back to normal.

Now here’s the kicker—this drug might actually work where others fail. There’ve been case studies showing that when tafenoquine is combined with standard meds, it’s clearing out the infection—especially in people who’ve had it relapse multiple times. That’s huge.

The trial itself? It’s kicking off enrollment in Q3 of 2025. It’s open-label, so no placebo games. They're tracking results over 90 days, looking at how well it works and how safe it is.

But zoom out for a second—babesiosis is on the rise, especially in the Northeast U.S. And guess what? There are zero FDA-approved treatments right now. None. If tafenoquine hits here, it could be a total game-changer.

The company’s saying the market could top 400,000 patients by the time their patent expires in 2035. That’s not small potatoes, dude.

Bottom line? This isn’t just a new drug play. This is one of those “holy sh*t, we might actually fix something no one’s talking about” situations. Definitely something to keep your eyes on.

If this hits? Game-changer.

And it’s Phase 2 right now—so this is where things start to get real. Early data drops, investor eyes, potential for partnerships or even big pharma attention.

I’m not saying it’s a guaranteed win—nothing is. But dude... if this works? That’s the kind of thing that goes from a couple bucks a share to “what the hell just happened?” overnight.

Watch this one. 60 Degrees Pharma. Nasdaq: SXTP.

Financially, they’re starting to flex. 2024, they pulled in over 600 grand in product revenue, which is a 140% jump. That’s not just growth—that’s a skyrocket. Gross profits flipped from a loss to a win. That’s a comeback story, man.

Plus, they just brought in cash—$4 million in a private placement, and another million-plus in early 2025. That’s real capital to fuel their R&D and marketing. They're putting it all into expanding ARAKODA and pushing new treatments to market.

Look, this isn't some pump-and-dump crypto coin. This is serious, science-backed, life-saving innovation. You want to read up on a company trying to make a difference? You want to read up on something that could literally save lives? This is where the smart money starts sniffing around.

Look—fundamentally? It’s a cool-ass story. No doubt.

But I’m a trader, man. I’m always hunting for that near-term potential, that "what’s about to happen right now" energy.

So yeah, that means it’s time to pull up the chart and see what’s really going on.

And dude—this thing’s a straight-up whippersnapper. It doesn’t just move, it launches. We’re talking 50% to 100%+ surges like it’s nothing. Not once, not twice—four full-on rocket moves in the past year.

It’s not just a chart. It’s a freakin’ launchpad.

• $14.76 to $35.99 in a day back in July? That’s a 143.8% gain. Insane.
  

• $5.60 to $11 during that August split? That’s 96.4%—nearly a double.
  

• $5.75 to $12.45 in just three days in December? That’s a 116.5% move—Merry freakin’ Christmas, indeed.
  

• $3.85 to $6 in a single day in January? That’s a 55.8% pop—boom.

All massive moves. Like, “drop your coffee” kind of gains.

Hey, have a look for yourself. Pull up SXTP on your trading platform this morning.

Eat. Sleep. TRADE!

Jason Bond

Questions or concerns about our products? Email [email protected] 

© Copyright 2022, RagingBull